Collection of news and reviews from CH3 with protein methylation in the cellular development of neuronal model systems
Continuing last week’s post about protein methylation in cellular inflammatory responses, we would like to call attention to the recent publication by Zhang et al. The authors explain how PRMT1-SMAD6 signaling may represent a new target for reducing the immune response in periodontitis (see Figure): Lipopolysacchride (LPS) from oral pathogens activate toll-like receptors (TLR) which […]
We are thinking a lot lately about the role of protein methylation in cellular inflammatory responses. The connection between the two is not a new idea. There are numerous clues in the primary scientific literature that functionally link protein methylation with inflammation. See for example the recent review by Webb and Guerau-de-Arellano There will be […]
This week’s blog post highlights a recent study by Lim et al. This proteome-wide analysis of protein arginine methylation in colorectal cancer based on human surgical specimens is another example of the developments occurring in our field with real impact on disease diagnosis. For histological detection of the methylation status of colon cancer, we recommend […]
CH3 BioSystems is excited about an important review article recently published by Majumder et al. that helps to explain the role of methylarginine modification in the functional regulation the fragile X family of proteins with implications for neurodevelopment and cancer. In conjunction with phospho-serine modifications of these methyl-proteins, the molecular mechanisms involved are likely to […]
A ground-breaking report from scientists at Glaxo and Epizyme has now revealed that the PRMT1 inhibitor, GSK3368715, exhibits potent anti-tumor activity. Extensive chemical and cellular studies support the usefulness of the new chemical compound as a First-In-Class therapeutic agent. Also described in the report are experiments that implicate the endogenous metabolic inhibitor, methyl-thioadenosine (MTA), in […]
The use of E0771 cells in cancer metastasis research is rapidly increasing in popularity. Researchers are attracted to the aggressive nature and immune system evading properties of the cells. One of the main interests of researchers using these cells is the role of immune cell antitumor functions in the regulation of cancer spread. Immune Responses […]
After removing E0771 cells from cell culture using sterile technique, the cells are counted and injected into a healthy mouse via the mammary pads (typically the fourth mammary pad) or intravenously in the tail vein [1-8]. To see the full effects of tumor growth, 1 x 105 to 1 x 106 must be used for […]
E0771 is a mouse breast adenocarcinoma cell line. The original source of E0771 cells was a spontaneously occurring breast tumor from C57BL/6 mouse [1]. The tumor was removed from the breast fat pad of the mouse and adapted for anti‐cancer drug testing by Sirotnak et al. in 1984 [2]. Cell culture conditions as described in […]
CH3 BIOSYSTEMS® On March 20, 2018 CH3 BIOSYSTEMS became a registered trademark for the protection of the unique R&D products produced in Buffalo, New York and sold to customers all over the world.
THE INTERSECTION OF CANCER AND PROTEIN METHYLATION William Pratt, CH3 Biosystems Lab Intern Introduction Protein arginine methyltransferases (PRMTs) are transcriptional coactivators, a type of coregulator that affects a transcription factor to increase the rate of transcription of a gene by recruiting general transcription machinery to the promoter region. The aberrant expression of PRMTs […]
